65,437 trials
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity (FVC) — -8.0; -10.0; -12.4 Change in Percent Predicted FVC
Left Ventricle Function
Primary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
Deep Venous Thrombosis
Primary: The Primary Outcome Measure Was the Number of Participants With New Heparin Platelet Factor 4 (HIT Positive) Antibodies in Each Group Within 30 Days Following Surgery…
Low Back Pain
Primary: Pain Assessed on a 10-point Numeric Pain Scale — 6.55; 6.68; 4.63; 5.13 cm
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks — -3.0; -4.8; -4.7; -5.5 Units on a scale — p=0.003
Healthy
Primary: Armodafinil DAT Occupancy in Caudate — 34.0; 60.5; 40.4; 65.2 μg/mL
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 12.3; 8.5 Weeks — p=0.3206
Reflux Episodes
Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations
Type 1 Diabetes
Primary: Change in A1C From Baseline to Week 15 — -1.7; -1.0 percent glycated hemoglobin
Generalized Anxiety Disorder
Primary: Effect of Escitalopram After 8 Weeks of Treatment in Patients With GAD Using the Hamilton Anxiety Scale (HAMA) — 13.1 scores on a scale
Migraine Disorders
Primary: Percent of Patient's Headaches With Pain Relief at 2 Hours After the Initial Dose of Test Drug — 80; 89.5; 69.6 percent of headaches
Facial Wrinkles
Primary: Change in Wrinkle Severity Rating Scale — -0.94; -1.07 units on scale
Social Anxiety Disorder
Primary: Effect of Escitalopram After 12 Weeks Using the Clinical Global Impression (CGI-I) — 2.1 scores on a scale
Osteoporosis
Primary: Number Adherent With the Intervention — 29 participants
Multiple Sclerosis, Relapsing-Remitting
Primary: Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) — 35.5; 40.9 weeks — p=0.1384